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OBJECTIVE—We studied whether manganese-enhanced high-
ﬁeld magnetic resonance (MR) imaging (MEHFMRI) could quan-
titatively detect individual islets in situ and in vivo and evaluate
changes in a model of experimental diabetes.
RESEARCH DESIGN AND METHODS—Whole pancreata from
untreated (n = 3), MnCl2 and glucose-injected mice (n = 6), and
mice injected with either streptozotocin (STZ; n = 4) or citrate
buffer (n = 4) were imaged ex vivo for unambiguous evaluation of
islets. Exteriorized pancreata of MnCl2 and glucose-injected mice
(n = 6) were imaged in vivo to directly visualize the gland and
minimize movements. In all cases, MR images were acquired
in a 14.1 Tesla scanner and correlated with the corresponding
(immuno)histological sections.
RESULTS—In ex vivo experiments, MEHFMRI distinguished
different pancreatic tissues and evaluated the relative abundance
of islets in the pancreata of normoglycemic mice. MEHFMRI also
detected a signiﬁcant decrease in the numerical and volume
density of islets in STZ-injected mice. However, in the latter
measurements the loss of b-cells was undervalued under the
conditions tested. The experiments on the externalized pancreata
conﬁrmed that MEHFMRI could visualize native individual islets
in living, anesthetized mice.
CONCLUSIONS—Data show that MEHFMRI quantitatively visu-
alizes individual islets in the intact mouse pancreas, both ex vivo
and in vivo. Diabetes 60:2853–2860, 2011
Despite the high incidence of diabetes, the pre-cise molecular and cellular mechanisms thatcause the decrease in the mass and function ofthe insulin-producing b-cells, observed in both
the type 1 and type 2 forms of the disease, remain to be
elucidated (1). At present, the only, although somewhat
indirect, way to monitor the onset and the evolution of the
diseases in a given individual is by using sensitive immu-
nological and functional tests, which require injections and
repeated blood sampling. However, we still lack a method
that could visualize and quantitate pancreatic b-cells in
vivo, in a fully noninvasive way. As a result, we also lack a
solid biological basis to target new therapeutic approaches
that could promote the regeneration (type 1 diabetes) or
the function (type 2 diabetes) of b-cells. The difﬁculty in
imaging these cells stems from their deep abdominal lo-
cation, their distribution in small (50–600 mm in diameter)
islets of Langerhans, their modest volume density (;1%)
in a control pancreas, and their close relationships
to different cell types of both endocrine and exocrine
nature.
Several of these issues have been partially solved using
optical methods, which can now investigate laboratory
rodents (2–4), but which cannot be adapted to human
studies, given the limited tissue penetration of light (2,4–6).
Penetration is not an issue in magnetic resonance (MR)
imaging (MRI) and positron-emitting tomography (PET)
imaging, which are convenient for human applications,
speciﬁcally if combined with computed tomography. Be-
cause islets are structurally and functionally heteroge-
neous, and are not all simultaneously altered to the same
degree during diabetes development, their individual vi-
sualization is important. The choice of an imaging modality
is then restricted to MRI, given that the lateral resolution
of PET is, at best, in the millimeter range (7). MRI has
already been used to visualize transplanted islets (8–11),
but has not yet been shown to detect native islets in situ,
mostly because of an insufﬁcient spatial resolution, which is
only provided by the use of a high magnetic ﬁeld (8,12–14).
The aim of the current study was to investigate whether
imaging of individual islets could be achieved using a 14.1
Tesla (T) MR scanner. In the absence of a validated probe
for the speciﬁc staining of b-cells, we have also tested
whether the MRI contrast of these islets could be en-
hanced by an in vivo infusion of manganese (12). Our data
document that the combination of these conditions, in
manganese-enhanced high-ﬁeld magnetic resonance im-
aging (MEHFMRI), allows for the easy differentiation
of multiple tissues within the whole murine pancreas,
including individual islets of Langerhans. The approach
quantitatively detects the loss of pancreatic islets in an
animal model of type 1 diabetes, and with this approach
pancreatic islets in the living animal can be investigated.
RESEARCH DESIGN AND METHODS
Animals. C57BL6 mice were used throughout. All animals were anesthetized
with an intraperitoneal injection of 1 g/kg body weight (b.w.) penthothal. Three
mice were immediately killed. Five mice had a polyethylene (PE50) catheter
with an adapted tip (Eppendorf, 0030 001.222) inserted into a femoral vein.
Through this catheter, a 15 mmol/L MnCl2 solution (in 0.9% NaCl) was infused
at the rate of 4 mL/h for 7 min, using a precision syringe pump. This provided
for a cumulative dose of 47 mg of MnCl2/kg b.w. Six other mice were given 0.8
g glucose/kg b.w. i.p. once, 15 min before the start of the manganese infusion.
After 30 min of the manganese infusion, the animals were again injected in-
traperitoneally with 1.7 g glucose/kg b.w., to acutely stimulate the b-cells, and
the pancreata were dissected 15 min later.
Four mice were injected intraperitoneally with 200 mg/kg b.w. streptozotocin
(STZ; Sigma), whereas four received only the citrate buffer (CB), which was used
as a vehicle of the drug. Two weeks later, the mice were anesthetized with 1.5%
isoﬂurane and had two intraperitoneal catheters placed for administration
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of 35 mg/kg b.w. MnCl2 dissolved in N,N-Bis(2-hydroxyethyl)glycine (BICINE)
buffer together with 1.5 g/kg b.w. glucose. Both MnCl2 and glucose were
manually injected via the catheters, while the animals were inside the magnet
bore of the MRI equipment as follows: ﬁrst, half of the MnCl2 dose (;1.5 mL)
was injected. After 25 min, all glucose and the second half of the MnCl2 solution
were injected. The animals were killed 2 h later, and pancreata were dissected
and ﬁxed.
Pancreas processing. At the end of each experiment, the entire pancreas was
rapidly dissected as one piece and placed in perﬂuoropolyether (Fomblin) within
a sealed plastic bag. Some pancreata were imaged fresh, immediately after the
sampling. Otherswere ﬁxed for 15 h in 4% paraformaldehyde (PFA) at 4°C,washed
in phosphate buffer, and placed individually into a Fomblin-containing bag.
MRI.Ex vivo pancreata were imagedwithin the Fomblin-containing bags, using
a 14.1 Tesla 26 cm horizontal bore scanner (Varian/Magnex Scientiﬁc, Abingdon,
U.K.) with a 12 cm inner-diameter gradient (400 mT/m in 200 ms, minimized eddy
currents), interfaced with a DirectDrive console (Varian, Palo Alto, CA) and
a quadrature half-volume coil of 20 mm diameter. High-resolution images were
acquired using a gradient echo multislice sequence with fourteen 0.3-mm-thick
slices, ﬁeld of view (FOV) 26*25 mm, and data matrix 512*512 (51*49*300 mm
resolution) to cover the whole mouse pancreas. T1/T2* weighted images with
repetition time (TR) = 282 ms, echo time (TE) = 7 ms, ﬂip = 60°, and 30 averages
were acquired for optimal tissue contrast in a 1 h 12 min acquisition time.
In vivo MRI was performed on externalized pancreata of six mice. Animals
were injected intraperitoneally with 35 mg/kg b.w. MnCl2 (dissolved in BICINE
buffer) and 1.5 g/kg b.w. glucose 2 to 3 h before anesthesia with 1 to 2% iso-
ﬂurane in a 3:2 air/O2 gas mixture. The abdomen was opened, and the spleen
was pulled out with the pancreas. The gland was secured to a Plexiglas plate
(Supplementary Fig. 1) using a plastic pin inserted between the pancreatic tail
and the spleen without damaging the pancreas vessels. Once the plastic pin
had been attached to a Plexiglas plate, the pancreas led on a semiﬂexible
plastic support to minimize its movements (Supplementary Fig. 1) and was
positioned in the center of a quadrature coil. The whole mounting was placed
within 5 min in the MRI equipment, in which the mouse was kept under
ventilation, anesthesia, and warmed by water circulation to maintain the body
temperature between 35° and 37°C. High-resolution images were acquired
using a gradient echo multislice sequence with 14 coronal 0.2-mm-thick slices,
FOV 26*26 mm, data matrix 382*382 (68*68*200 mm resolution), and 10 aver-
ages. To prevent inference of respiratory movements, images were acquired by
gating on the breathing cycle and recorded with TR ;700 ms, TE = 5 ms, and
ﬂip = 60° in ;1 h.
Histology. After in vivo MRI, pancreata were ﬁxed in Bouin’s ﬁxative solution
(14 g/L of picric acid, 8% formol, and 4% acetic acid) for at least 48 h. All
pancreata were washed, dehydrated, and embedded in parafﬁn, keeping the
same orientation that was used during MRI acquisition. Serial sections of 5 mm
thickness were cut through the MR imaged samples, stained with hematoxylin-
eosin, digitized using a MIRAX MIDI slide scanner (Zeiss), and analyzed using
the MIRAX Viewer software.
Sections from ex vivo imaged pancreata were sequentially passed into
Neoclear, twice for 5min, and then in 100 (twice), 95, 70, 50, and 30% ethanol for
3 min each. The sections were incubated for 1 h in 10 mmol/L NH4Cl in PBS to
remove PFA excess, followed by 30 min in a 0.5% BSA solution in PBS. Sec-
tions were stained with either antiglucagon mouse antibody (Sigma) diluted
1/40,000 or anti-insulin guinea pig antibody (Ventrex 675) diluted 1/2,000, for
2 h at room temperature. Thereafter, sections were incubated with donkey
anti-mouse ﬂuorescein isothiocyanate (1/400; P.A.R.I.S.) and goat anti–guinea
pig-Alexa 488 (1/500; Molecular Probes), respectively, for 1 h at room temperature.
Sections were counterstained with 0.03% Evans Blue, coverslipped, and scanned
using the MIRAX equipment, operated under ultraviolet rays illumination.
Quantitative analysis. MRI images were analyzed using Matlab R2008a
(Math-Works, Natick, MA). The entire pancreas proﬁle and all detectable hy-
perintense, putative islet-like structures were manually outlined. These regions
of interest were used to determine the location, size, shape, number, cross-
sectional area, volume, and relative signal intensity.
Sections (5 mm thick) of the same pancreas that had been imaged by MR
were stained with hematoxylin-eosin, scanned, and quantitatively evaluated
with the MIRAX Viewer software, for evaluation of islet size, volume, and
numerical density.
Statistics. Values are shown as means + SEM and were compared using
unpaired t tests as provided by SPSS (Chicago, IL). Because of the skewed
distributions, islet sizes were compared using the nonparametric Mann-Whitney
and Kolmogorov-Smirnov tests, also provided by SPSS.
RESULTS
Ex vivo MRI of the intact mouse pancreas. MRI (14.1T)
was used to image the entire mouse pancreas in slices
of 300 mm thickness and with a 50 mm in plane resolution.
In the absence of a contrast agent, the images showed the
lobular structure of the gland (Fig. 1A and Supplementary
Fig. 2) and, within these lobules, occasional round-ovoid
whitish bodies that corresponded in shape, size, and dis-
tribution to putative individual islets (Fig. 1B and Supple-
mentary Fig. 2). Other, much larger structures were located
between the pancreatic lobules (Fig. 1C). After infusion
of manganese and injection of a glucose dose known to
stimulate b-cells, the contrast of the lobular and inter-
lobular structures was enhanced (Fig. 1C and Supplemen-
tary Fig. 2).
Histology validates the pancreas substructures imaged
by MRI. To positively identify the pancreas structures seen
by MRI, we processed each pancreas for histology and
screened the sections that were the closest to the plane of
the MRI image recorded within the 300-mm-thick tomogra-
phic slice of the samples (Figs. 1C and 2A). The presence
in both images of ducts and vessels, as well as non-
pancreatic tissues, helped precisely match the MRI and the
histological images. This procedure conﬁrmed the different
appearance of the pancreas and close-by organs (such
as spleen or intestines) and differentiated, within the gland,
the lymphatic ganglia from the adjacent exocrine tissue
(Fig. 1C). Moreover, higher magniﬁcation views of both
MR images and corresponding histological sections con-
ﬁrmed that the small, round-ovoid structures scattered
within the exocrine pancreas were bona ﬁde pancreatic is-
lets of Langerhans (Fig. 2A). In the MRI images of pancreata
from mice that had not been infused with manganese, islets
were also occasionally visible as hyperintense whitish bod-
ies (Fig. 1B). However, the intensity of the islet signal, rel-
ative to that of the adjacent exocrine pancreas, was
somewhat higher (P , 0.001, n = 27) after manganese in-
fusion than in the noninfused controls (Fig. 2B).
Quantiﬁcation of the islet mass by MRI. To compare
the size of putative islets as well as their numerical and
volume densities within the pancreas, the entire pancreata
of ﬁve animals that had received both manganese and
glucose were evaluated ﬁrst by MRI and then by histology
(Fig. 3A). Morphometry showed the expected asymmetrical
distribution of islet sizes in histological sections (Fig. 3B).
The size distribution determined by the MRI was signiﬁ-
cantly (P , 0.001) shifted to higher diameters, likely a re-
sult of partial volume effects of the 300 mm slice thickness,
which made the detection of islets ,50 mm in diameter
difﬁcult (Fig. 3B). Despite this limitation, MRI evaluated
that the volume density of islets, i.e., the relative volume of
islets within the pancreas, was on the average 0.8 6 0.2%
(n = 5; Fig. 3C). The average numerical density of islets
was 1.2 6 0.3 per mm3 of pancreas (n = 5).
To evaluate whether the loss of islets in an animal model
of type 1 diabetes can be detected by MRI, we injected
mice intraperitoneally with either 200 mg/kg b.w. STZ or
an equivalent volume of the CB (sham treatment), which
was used as vehicle for the drug (Fig. 4A). Two weeks
after the STZ injections MRI evaluation showed that the
hyperglycemic mice (Supplementary Table 1) had a pan-
creas volume (Vp; bottom panel of Fig. 4B) that was not
signiﬁcantly different from that of the citrate-injected
controls. In contrast, the relative number (Nvi; top panel of
Fig. 4B) and volume density (Vvi; middle panel of Fig. 4B)
of the islets were decreased by 55% (P , 0.01) and 45%
(P, 0.001), respectively, in the STZ-injected mice (Fig. 4B).
These changes were conﬁrmed by the histological analysis
of the same pancreas (Fig. 4A). Given that the hypergly-
cemia of the STZ-injected mice (Supplementary Table 1)
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suggested a more profound drop of the insulin-producing
b-cells, we immunostained the pancreas for insulin and glu-
cagon (Fig. 4C). As expected, we found that the islets of the
STZ-injected mice contained much less insulin-containing
b-cells than those of controls. However, anti-glucagon
staining demonstrated an increased number of glucagon-
containing a-cells (Fig. 4C). In some cases, the latter cell
type occupied almost the entire surface of the small, re-
sidual islets (Fig. 4C).
Visualization of islets by Mn2+-enhanced MRI in living
mice. To determine whether high-ﬁeld MRI can detect
islets in vivo, the pancreas was exteriorized through an
abdominal incision, without affecting its normal blood ﬂow
and innervation (Supplementary Fig. 1). This externalization
FIG. 1. High-resolution MRI reveals the structure of the entire mouse pancreas. A and B: Whole mouse pancreata (300-mm-thick slices) were imaged
ex vivo, with 50 mm in plane resolution (TR/TE = 282/7 ms). A: In an image obtained without contrast agent, pancreatic lobules are seen, most of
which feature a somewhat homogeneous and structureless content at this low magniﬁcation. Scale bar: 1 mm. B: Under these conditions, MRI
infrequently identiﬁed putative islets of Langerhans (green arrows) within the intact pancreas. Scale bar: 1 mm. C: The contrast of pancreatic
lobules was enhanced after intravenous infusion of MnCl2 combined with an intraperitoneal injection of glucose. Under these conditions, MRI
allowed to distinguish whitish tubular structures, as well as highly contrasted round-ovoid structures of various sizes. The smallest of these
structures (<0.5 mm; green arrows) was observed within the pancreatic lobules. Larger structures (>1 mm) were seen between the lobules. The
latter structures were identiﬁed by histological analysis of the very same pancreas, conﬁrming that MRI differentiates the pancreatic parenchyma
from intrapancreatic lymphatic ganglia (C1), spleen (C2), and loops of small intestine (C3). Scale bar: 1 mm in A–C; 0.5 mm in lower panels B1–3.
(A high-quality digital representation of this ﬁgure is available in the online issue.)
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minimized the effects of breathing and bowel movements
on imaging and allowed for the unambiguous identiﬁcation
of the pancreas, which is not immediate in the noninvasive
imaging of mice. Under these conditions, MRI revealed
intrapancreatic structures similar to those observed in
the ex vivo samples, including putative pancreatic islets
of Langerhans, which appeared as intralobular whitish
bodies (Fig. 5). Correlative histology conﬁrmed that these
bodies were bona ﬁde islets (Fig. 5).
DISCUSSION
Imaging the pancreatic islets, which comprise all insulin-
producing b-cells of our body and most of its glucagon-
producing a-cells, is urgently needed to progress in our
understanding of the natural history and the pathophysi-
ology of diabetes, as well as to monitor candidate treat-
ments aimed at compensating and improving, if not curing,
the disease (15,16). Although progress has been made in
the imaging of transplanted islets, which can be labeled
before transplantation (8–11,17,18), the imaging of the
native islets within an entire, intact pancreas still raises
signiﬁcant challenges. This is because of the small size of
pancreatic islets, their scattering within the pancreas, their
poor contrast relative to that of the surrounding tissues,
and the deep position of the pancreas within the abdomen.
In laboratory mice, at least some of these challenges can
be solved using b-cell–speciﬁc probes and near-infrared
optical methods (19). However, in larger animals and in
humans, the use of nonoptical methods, such as PET or
MRI, is required, because of the limited tissue penetration
of light (15,16,20,21). If PET has a unique sensitivity and
is quantitative, it lacks the resolution to differentiate in-
dividual islets, and its application to large numbers of
individuals is complicated by the need to generate positron-
emitting isotopes, the short half-life of these compounds,
and a variety of safety issues. MRI is of more widespread
applicability, but questions arise as to whether it could vi-
sualize the small pancreatic islets, which in a control hu-
man pancreas represent all together no more than 1 g wet
weight tissue, and, furthermore, whether it is amenable to
a sound quantitative analysis of their mass and function
(15,16,21,22).
Using the increased sensitivity of a 14.1T MRI system,
we achieved a spatial resolution (23) that, on theory,
should be sufﬁcient to detect islets. Using a correlative
MRI-histology approach, we document here that the tech-
nique indeed visualizes individual islets within a whole,
fresh, and untreated mouse pancreas, after either excision
of the gland or its externalization in a living mouse. We
further document that the islet visualization is enhanced
by the prior vascular infusion of manganese (12,14,24,25),
particularly in animals challenged with an acute glucose
load, since the cation accumulates in islet cells during
stimulation of insulin secretion (12,14,24). The study pro-
vides evidence that a clinically relevant imaging method-
ology can be adapted to image individual pancreatic islets
in the intact rodent pancreas.
Our study further shows that the analysis of MEHFMRI
images provides a sound estimate of the islet mass in
control mice. Thus, both the numerical and volume density
estimates of the endocrine islets were consistent with the
many previous reports, which evaluated these parameters
by morphometry of histological sections (26–30). However,
the volume and number of the islets were underestimated
by MEHFMRI, presumably as a result of the so-called partial
volume effect (31,32), as small islets (,50 mm in diameter),
which represent but a small proportion of the total b-cell
volume, escaped MRI detection within the 300-mm-thick
pancreas slices that we imaged. Our study also provides
evidence that MRI can quantitate a partial loss of islets, as
a result of a major cytotoxic insult to b-cells. Thus, 2 weeks
after administration of a dose of STZ, which made the
animals stably and overtly hyperglycemic, MRI revealed
a 45–55% loss in the volume and numerical densities of the
endocrine islets. Immunolabeling of the same pancreas
showed that, as expected from many previous reports
(31–40), the loss of b-cells was sizably larger than suggested
by this percentage and was associated to the persistence
of many glucagon-containing a-cells (38,41). Thus, under
the conditions we used, MRI did not differentiate the islets
FIG. 2. Individual pancreatic islets are visualized by MRI. A: This
MR image (left) is a high magniﬁcation view of the pancreas shown in
Fig. 1C, recorded with a 50 mm in plane resolution. Small, round-ovoid
whitish structures (several are pointed by green arrows) are seen dis-
persed within the pancreatic lobules. Histology (right) conﬁrmed that
these structures are pancreatic islets of Langerhans, dispersed within
the exocrine parenchyma, between vessels and ducts (white arrows).
Scale bar: 1 mm. B: Quantiﬁcation of the islet signal intensity, relative to
that of the surrounding exocrine tissue, conﬁrmed that the MR image of
islets was more contrasted (***P < 0.001) in the Mn2+-infused mice (red
bar) than in noninfused controls (blue bar). Values are means + SEM of
the number of islets indicated within the columns. a.u., Arbitrary units.
(A high-quality digital representation of this ﬁgure is available in the
online issue.)
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containing residual b-cells from those predominantly made
of a-cells, most likely because manganese is taken up by
multiple pancreatic cell types, including a-cells (42,43).
These considerations raise concerns that MEHFMRI may
not be adequate to detect the modest loss in b-cell mass
that may progressively take place over months of diabetes
development, nor the even more modest increase in b-cell
numbers, which could be anticipated under conditions
of spontaneous or treatment-induced b-cell proliferation,
transdifferentiation, or neogenesis. To increase the sensi-
tivity of the approach, the development of ligands spe-
ciﬁcally targeting b-cells (19) is most needed. With the
availability of such ligands, MRI may become useful for the
evaluation and longitudinal monitoring of both type 1 and
type 2 diabetes (4,44–47).
Given the present methodological stage of these experi-
ments, we focused on the MRI of islets in either ex vivo or
exteriorized mouse pancreas. The obvious next step is to
test whether the approach is amenable to the quantitative
imaging of native islets, under noninvasive, in vivo con-
ditions. This question raises signiﬁcant challenges. First,
an in vivo MRI should take into consideration the circu-
latory, respiratory, and intestinal movements of the living
animal, which cyclically displace the islets by a factor sig-
niﬁcantly larger than their average diameter. To compen-
sate for these movements, the image acquisition needs to be
FIG. 3. MRI quantiﬁes islet mass and size. A: Islets of different sizes were detected in the MR images of whole mouse pancreas (top) and conﬁrmed
by correlative histology (bottom). The right panels are enlargements of the regions boxed in the left panels. Scale bar: 1 mm. B: Islet sizes were
measured in both MR and histology images. The distribution of the values was asymmetrical in both cases, conﬁrming that islets <150 mm in
diameter predominate in the control mouse pancreas, whereas islets>300 mm are rare. Of note, islets <50 mm in diameter escaped MRI detection.
C: Further morphometric evaluation of MR images showed that MRI detected on the average 1 islet /mm3 of pancreas (left), accounting for
a relative volume of the endocrine micro organs of 0.86 0.2% (middle). A mean of 268 islets per animal (n = 5) was detected; Vvi, volume density of
islets; Nvi, volume density of the islets (Ni/mm
3 of pancreas); Vp, total volume of pancreas analyzed (mm3). Values are means + SEM of ﬁve control
mice. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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synchronized with the breathing and beating cycles, which
is achievable with modern equipment. Second, a major
limitation of pancreas MRI in the living rodent results from
the small size of the gland and its intricate topography with
respect to the other abdominal organs. The MRI deﬁnition
of the rodent pancreas is therefore cumbersome and, to
some extent, ambiguous. A solution to this problem awaits
the development of a second, still putative ligand labeling
FIG. 4. MRI detects the loss of islets in a diabetic mouse model. A: High magniﬁcation MR and histology images of pancreas from mice injected with
either CB (normoglycemic controls) or the buffer supplemented with STZ (hyperglycemic mice). Whitish (MRI)/pink islets (histology) were seen
more frequently in the pancreata of control rather than of STZ-injected mice (some islets are pointed by green arrows). Scale bar: 1 mm and 0.5 mm
in the insets. B: Morphometric analysis of the MR images showed that hyperglycemic mice had a pancreas volume (Vp; bottom) that was not
signiﬁcantly different from that of the citrate-injected controls. In contrast, the relative number (Nvi; top) and volume density (Vvi;middle) of the
islets were decreased by 55 and 45%, respectively, in the STZ-injected mice. Data are mean + SEM of the indicated number of pancreas (**P< 0.01;
*** P < 0.001). C: Immunostainings of consecutive pancreas sections of control and STZ-treated mice with antibodies against insulin and glucagon
show that the STZ treatment signiﬁcantly reduced the number of b-cells in most islets (outlined by white dotted lines). Most islets still contained
many glucagon-containing a-cells. Some small islets (arrows) were essentially made by the latter type of islet cells and were fully devoid of insulin-
containing cells. Scale bar: 0.5 mm. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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the entire exocrine tissue. This issue, however, is unlikely
to limit the future translation of MRI to image the human
pancreas, which features a much denser and more com-
pact anatomy. In contrast, the future translation of MRI to
the diabetes clinic faces several other problems, including
the technical conditions required to obtain a sufﬁciently
contrasted (manganese infusion) and resolutive image (high
magnetic ﬁeld). With regard to contrast, manganese infusion
certainly raises safety questions. However, this potential
problem may be overcome, and manganese-enhanced MRI
is now routinely used in many clinical centers (31,32). The
cation may also be replaced by alternative T1-relaxing
agents (48), awaiting the availability of safer ligands to
natural moieties of the b-cell membrane (19). With regard
to resolution, the high magnetic ﬁeld that is required, and
that we used here, presently limits the approach to research
on animal models until safety concerns have been ade-
quately dealt with. However, the recent introduction of high
ﬁeld (3–9.4 T) equipment for whole human body MRI opens
the possibility to now achieve in humans (49) a signiﬁcant
islet imaging, also because the manganese enhancement
should be anticipated to be better than under the 14.1T
conditions we tested here (50).
At any rate, the major goal of this study was to provide
a ﬁrst proof-of-principle that a clinically relevant imaging
method can be developed to quantitatively visualize native
islets in the mouse. The positive answer to this question,
which is provided by our study, now opens the way to the
MRI analysis of a variety of models that have been gener-
ated in this animal species, to address unanswered ques-
tions about the pathophysiology and sequence of the events
that lead to diabetes.
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